1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung ...
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click to read the study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No ...
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
